Marshall Wace
AMLX icon

Marshall Wace’s Amylyx Pharmaceuticals AMLX Stock Holding History

Marshall Wace’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-247,275
Closed -$875K – 2667
2025
Q1 		$875K Buy
247,275
+62,597
+34% +$223K ﹤0.01% 1846
2024
Q4 		$698K Sell
184,678
-99,308
-35% -$467K ﹤0.01% 1896
2024
Q3 		$920K Buy
+283,986
New +$638K ﹤0.01% 1682
2024
Q1 		– Sell
-985,114
Closed -$14.5M – 2407
2023
Q4 		$14.5M Sell
985,114
-212,646
-18% -$3.26M 0.02% 576
2023
Q3 		$21.9M Sell
1,197,760
-782,420
-40% -$16.5M 0.04% 407
2023
Q2 		$42.7M Buy
1,980,180
+840,940
+74% +$22.7M 0.08% 261
2023
Q1 		$33.4M Buy
+1,139,240
New +$39.6M 0.07% 304
2022
Q4 		– Sell
-341,064
Closed -$9.6M – 2907
2022
Q3 		$9.6M Sell
341,064
-317,309
-48% -$7.92M 0.02% 918
2022
Q2 		$12.7M Buy
658,373
+73,909
+13% +$877K 0.03% 705
2022
Q1 		$7.51M Buy
+584,464
New +$13.2M 0.01% 1076

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Marshall Wace's AMLX Position: Q2 2025 in Review

Marshall Wace sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 247,275 shares — an estimated $875K sold.

Marshall Wace first reported a position in AMLX in Q1 2022 and held it in 10 quarters. The position peaked at $42.7M in Q2 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Marshall Wace reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 247,275 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $875K.
  • Marshall Wace first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Marshall Wace's Amylyx Pharmaceuticals position peaked at $42.7M in Q2 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.